Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
TMS Co., Ltd. (4891.T)
Fuchu, JP
Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceuticals, quasi-drugs, drug substances, medical devices, and various medical commodities. The company's pipeline includes TMS-007, an SMTP congener demonstrating both prothrombolytic and anti-inflammatory/antioxidative activities, which has advanced through Phase 2a clinical trials for the treatment of acute ischemic stroke. Additionally, TMS-008, another SMTP congener with anti-inflammatory/antioxidative properties, is undergoing nonclinical development for addressing inflammatory complications like acute kidney injury and cancer cachexia. A third product candidate, TMS-009, is currently in preclinical development. TMS Co., Ltd. collaborates with Hokkaido University and Kanazawa University to assess the potential of its drug candidates, has a joint research agreement with Teikyo University to identify renal function biomarkers, and maintains a strategic alliance with Ji Xing Pharmaceuticals Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.60% | -1.37% | +1.41% | +1.41% | +2.86% | +9.09% | -7.10% | -48.94% | -81.27% | -81.27% | -81.27% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-17.8% Q1'26: +11.6% (vs Q4'24)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +1,543.6% (vs Q4'24)
-
Share dilution Biotechnology: -3.4%+10.4% Q1'26: +12.8% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Feb 2024 actual |
Feb 2025 actual |
Feb 2025 actual |
Dec 2025 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 700.00M (-100.0%)
|
—
|
—
|
—
est: 468.75M (-100.0%)
|
—
est: 468.75M (-100.0%)
|
468.75M
468.75M – 468.75M
+0.0% YoY
|
469.00M
469.00M – 469.00M
+0.1% YoY
|
39.00M
39.00M – 39.00M
-91.7% YoY
|
187.50M
187.50M – 187.50M
+380.8% YoY
|
| EBITDA |
-937.00M
est: 641.73M (-246.0%)
|
-655.89M
|
-836.05M
|
-836.05M
est: 429.73M (-294.6%)
|
-655.89M
est: 429.73M (-252.6%)
|
429.73M
429.73M – 429.73M
+0.0% YoY
|
429.96M
429.96M – 429.96M
+0.1% YoY
|
35.75M
35.75M – 35.75M
-91.7% YoY
|
171.89M
171.89M – 171.89M
+380.8% YoY
|
| EBIT |
-943.00M
est: 641.68M (-247.0%)
|
-659.60M
|
-836.37M
|
-836.37M
est: 429.70M (-294.6%)
|
-659.60M
est: 429.70M (-253.5%)
|
429.70M
429.70M – 429.70M
+0.0% YoY
|
429.92M
429.92M – 429.92M
+0.1% YoY
|
35.75M
35.75M – 35.75M
-91.7% YoY
|
171.88M
171.88M – 171.88M
+380.8% YoY
|
| Net Income |
-960.04M
est: -80.64M (-1,090.6%)
|
-660.55M
est: -1.05B (+37.1%)
|
-859.27M
est: -1.05B (+18.2%)
|
-859.27M
est: -1.96B (+56.1%)
|
-660.55M
est: -1.96B (+66.3%)
|
-1.13B
-1.13B – -1.13B
+42.5% YoY
|
-1.08B
-1.08B – -1.08B
+4.3% YoY
|
-1.47B
-1.47B – -1.47B
-36.4% YoY
|
-1.51B
-1.51B – -1.51B
-2.7% YoY
|
| SGA |
313.00M
est: 596.44M (-47.5%)
|
286.65M
|
288.02M
|
288.02M
est: 399.40M (-27.9%)
|
286.65M
est: 399.40M (-28.2%)
|
399.40M
399.40M – 399.40M
+0.0% YoY
|
399.61M
399.61M – 399.61M
+0.1% YoY
|
33.23M
33.23M – 33.23M
-91.7% YoY
|
159.76M
159.76M – 159.76M
+380.8% YoY
|
| EPS |
-26.02
est: -2.00 (-1,201.0%)
|
-16.38
est: -26.05 (+37.1%)
|
-19.30
est: -26.05 (+25.9%)
|
-19.30
est: -44.00 (+56.1%)
|
-16.38
est: -44.00 (+62.8%)
|
-25.28
-25.28 – -25.28
+42.5% YoY
|
-24.18
-24.18 – -24.18
+4.3% YoY
|
-32.98
-32.98 – -32.98
-36.4% YoY
|
-33.87
-33.87 – -33.87
-2.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Keiji Hasumi | Founder, Chief Scientific Officer & Chairman | — | — |
| Koji Ohe | General Counsel | — | — |
| Naohisa Yokota | Executive Vice President of Development & Director | — | — |
| Takuro Wakabayashi | President, Chief Executive Officer & Representative Director | — | male |
| Tsuyoshi Ito | Director & Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4891.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
